AR and metastatic prostate carcinoma: One such recent study showed that expression of AR-V7 of the AR in CTCs was correlated with poor patient response to abiraterone and enzalutamide therapy in metastatic prostate cancer (Sciarra et al., 2019), and thus CTC analyses may be a useful tool for the prediction of treatment response and to inform therapy decision making.